JP6023097B2 - Ｎカルボキシアルキルオーリスタチンおよびその使用 - Google Patents
Ｎカルボキシアルキルオーリスタチンおよびその使用 Download PDFInfo
- Publication number
- JP6023097B2 JP6023097B2 JP2013558400A JP2013558400A JP6023097B2 JP 6023097 B2 JP6023097 B2 JP 6023097B2 JP 2013558400 A JP2013558400 A JP 2013558400A JP 2013558400 A JP2013558400 A JP 2013558400A JP 6023097 B2 JP6023097 B2 JP 6023097B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- methyl
- compound
- methoxy
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11158481 | 2011-03-16 | ||
| EP11158481.9 | 2011-03-16 | ||
| PCT/EP2012/054294 WO2012123423A1 (de) | 2011-03-16 | 2012-03-12 | N-carboxyalkyl-auristatine und ihre verwendung |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016145282A Division JP2016185987A (ja) | 2011-03-16 | 2016-07-25 | Ｎカルボキシアルキルオーリスタチンおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515735A JP2014515735A (ja) | 2014-07-03 |
| JP2014515735A5 JP2014515735A5 (cg-RX-API-DMAC7.html) | 2015-07-02 |
| JP6023097B2 true JP6023097B2 (ja) | 2016-11-09 |
Family
ID=45812791
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558400A Active JP6023097B2 (ja) | 2011-03-16 | 2012-03-12 | Ｎカルボキシアルキルオーリスタチンおよびその使用 |
| JP2016145282A Withdrawn JP2016185987A (ja) | 2011-03-16 | 2016-07-25 | Ｎカルボキシアルキルオーリスタチンおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016145282A Withdrawn JP2016185987A (ja) | 2011-03-16 | 2016-07-25 | Ｎカルボキシアルキルオーリスタチンおよびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9029406B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2686336B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6023097B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103764667B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2829736C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2543888T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012123423A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2621508B1 (de) | 2010-09-29 | 2015-08-26 | Seattle Genetics, Inc. | N-carboxyalkyl-auristatine und ihre verwendung |
| CN103826661B (zh) * | 2011-04-21 | 2019-03-05 | 西雅图基因公司 | 新的结合剂-药物缀合物(adc)及其用途 |
| EP2780039B9 (en) | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
| WO2014093379A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| US9988420B2 (en) | 2013-12-17 | 2018-06-05 | Novartis Ag | Cytotoxic peptides and conjugates thereof |
| EP3086815B1 (en) | 2013-12-27 | 2022-02-09 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
| MY186711A (en) | 2014-04-25 | 2021-08-12 | Pf Medicament | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer |
| RU2685259C2 (ru) | 2014-04-25 | 2019-04-17 | Пьер Фабр Медикамент | Конъюгат антитела и лекарственного средства и его применение для лечения рака |
| EA201692530A1 (ru) | 2014-06-13 | 2017-07-31 | Новартис Аг | Цитотоксические пептиды и их конъюгаты |
| CN110234348B (zh) | 2016-12-16 | 2024-06-25 | 蓝鳍生物医药公司 | 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法 |
| CN111393346B (zh) * | 2020-06-02 | 2020-08-25 | 凯莱英生命科学技术(天津)有限公司 | N-Boc-Dolaproine及Boc-Dap DCHA的合成方法 |
| AU2022338463A1 (en) | 2021-09-03 | 2024-03-21 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| WO1999035164A1 (en) | 1998-01-09 | 1999-07-15 | Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University | Anti-cryptococcal peptides |
| WO2000069472A2 (en) | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6737409B2 (en) * | 2001-07-19 | 2004-05-18 | Hoffmann-La Roche Inc. | Dolastatin 10 derivatives |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| EP2353611B1 (en) | 2002-07-31 | 2015-05-13 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| KR101520209B1 (ko) * | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| EP1817336B1 (en) | 2004-11-12 | 2019-01-09 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
| US8343928B2 (en) | 2005-07-07 | 2013-01-01 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| RU2483080C2 (ru) | 2006-10-27 | 2013-05-27 | Дженентек, Инк. | Антитела и иммуноконъюгаты и их применение |
| ES2523033T3 (es) | 2008-03-18 | 2014-11-20 | Seattle Genetics, Inc. | Conjugados enlazadores del fármaco auriestatina |
| JP5791707B2 (ja) * | 2010-06-10 | 2015-10-07 | シアトル ジェネティックス， インコーポレイテッド | 新規アウリスタチン誘導体およびその使用 |
| EP2621508B1 (de) * | 2010-09-29 | 2015-08-26 | Seattle Genetics, Inc. | N-carboxyalkyl-auristatine und ihre verwendung |
| CN103826661B (zh) | 2011-04-21 | 2019-03-05 | 西雅图基因公司 | 新的结合剂-药物缀合物(adc)及其用途 |
-
2012
- 2012-03-12 CN CN201280019732.4A patent/CN103764667B/zh active Active
- 2012-03-12 JP JP2013558400A patent/JP6023097B2/ja active Active
- 2012-03-12 WO PCT/EP2012/054294 patent/WO2012123423A1/de not_active Ceased
- 2012-03-12 ES ES12708034.9T patent/ES2543888T3/es active Active
- 2012-03-12 US US14/004,699 patent/US9029406B2/en active Active
- 2012-03-12 CA CA2829736A patent/CA2829736C/en active Active
- 2012-03-12 EP EP12708034.9A patent/EP2686336B1/de active Active
-
2016
- 2016-07-25 JP JP2016145282A patent/JP2016185987A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN103764667B (zh) | 2017-06-20 |
| WO2012123423A1 (de) | 2012-09-20 |
| US9029406B2 (en) | 2015-05-12 |
| CA2829736C (en) | 2020-07-21 |
| EP2686336B1 (de) | 2015-05-06 |
| EP2686336A1 (de) | 2014-01-22 |
| ES2543888T3 (es) | 2015-08-25 |
| CA2829736A1 (en) | 2012-09-20 |
| CN103764667A (zh) | 2014-04-30 |
| JP2016185987A (ja) | 2016-10-27 |
| JP2014515735A (ja) | 2014-07-03 |
| US20140080763A1 (en) | 2014-03-20 |
| HK1191034A1 (en) | 2014-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6023097B2 (ja) | Ｎカルボキシアルキルオーリスタチンおよびその使用 | |
| JP5791707B2 (ja) | 新規アウリスタチン誘導体およびその使用 | |
| JP5933562B2 (ja) | Ｎ−カルボキシアルキル−アウリスタチンおよびその使用 | |
| EP2699268A2 (de) | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung | |
| EP2790731A2 (de) | Fgfr-binder-wirkstoff konjugate und ihre verwendung | |
| HK1191034B (en) | N-carboxyalkyl-auristatins and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150511 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160226 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160525 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160725 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161004 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161006 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6023097 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |